Managing Enterprise Risk in Life Sciences: An In-House Perspective

Managing Enterprise Risk in Life Sciences: An In-House Perspective

View Session Speakers

Life sciences companies operate in a uniquely high-risk environment where scientific uncertainty, regulatory scrutiny, IP exposure, supply-chain fragility, and litigation risk all converge. In-house teams sit at the center of this complex risk matrix, and they are forced to make real-time decisions that balance innovation speed, compliance, capital efficiency, and long-term value creation. Unfortunately, imperfect information and competing internal pressures only compound what is already extremely challenging.

This panel delivers a candid, in-house view of how enterprise risk is identified, prioritized, and managed inside life sciences organizations. Panelists will discuss how legal, IP, regulatory, and compliance functions integrate with R&D, commercial, and executive leadership to anticipate risk rather than react to it. The conversation will focus on how risk tolerance is set, how trade-offs are evaluated, and where breakdowns most commonly occur.

Topics will include IP and exclusivity risk, clinical and regulatory uncertainty, contracting and partnering exposure, data and AI governance, litigation strategy, and board-level risk reporting. Panelists will also address how in-house teams allocate limited resources, influence decision-making without slowing innovation, and build credibility as strategic advisors rather than gatekeepers.

Survey: https://www.surveymonkey.com/r/Managing-Enterprise-Risk-in-Life-Sciences